New Inkjet-Printed Diagnostics-on-Demand Demonstrated at AACC 2015
|
By LabMedica International staff writers Posted on 17 Aug 2015 |

Image: The new “XylemDx” inkjet printing based technology turns a sheet of paper into any one of a variety of rapid, lower-cost tests. Each can be configured with a custom set of test modules before being folded concertina-style into the traditional test cartridge shape (Photo courtesy of Cambridge Consultants).

Image: Example of an open diagnostic test cartridge made using the breakthrough “XylemDx” inkjet printing based technology to custom-print any one of a variety of test modules onto a single sheet of paper (Photo courtesy of Cambridge Consultants).
An inkjet-based innovation for high-tech printing on paper opens the door to lower cost, rapid (point-of-care) POC testing, and was demonstrated during the 2015 AACC Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA).
The new XylemDx technology developed Cambridge Consultants (Cambridge, UK) is set to bring a breakthrough innovation to POC diagnostics. Ingenious use of inkjet printing techniques has made it possible to create a test cartridge from a single sheet of paper, paving the way for sophisticated low-cost tests that can be adapted at the touch of a button. Also, the digital fabrication technique (once regulatory approval is secured) will give the flexibility to print tests in quantities from one to millions.
Aging populations, the drive for healthcare efficiency, and the rapid rise of “consumer healthcare”—where people manage their own health and well-being—are fueling an increase in POC diagnostics. But the high cost of POC tests compared with centralized lab tests is a challenge. XylemDx enables simple, low-cost, near-instant personalized testing, for example, at the pharmacy or doctor’s surgery, for signs ranging from the latest strain of the flu virus to biomarkers for genetic conditions. In developing countries, it could play a crucial role in mobile-clinic diagnostics and in pandemic monitoring and screening of large populations during an outbreak of Ebola, for example.
XylemDx turns a sheet of paper into any one of a variety of different tests, each of which can be produced on the same fabrication device. Each test paper can be configured with a custom set of test modules (such as electronic, thermal, fluidic, optical, or biological reagent modules) before being folded concertina-style into the traditional test cartridge shape. For diagnostic manufacturers, this opens up the possibility of low-cost prototyping and development, as well as a universal production methodology. The modules “toolbox” enables customization for a particular patient or specific strain of disease.
The test modules are printed with inkjet-based printing techniques that use wax to lay down fluidic pathways, electronic ink containing silver nanoparticles to allow electrical connectivity, and so on. The paper cartridges can be configured for various samples types (such as blood, urine, saliva, or mucus) and various readers (from complex diagnostic instruments to a reader on the back of a smartphone or a simple USB-powered device).
“Diagnostic tests underpin crucial healthcare decisions so it’s vital they are as fast, accurate, flexible, and cost-effective as possible,” said John Pritchard, head of diagnostics at Cambridge Consultants, “Cambridge Consultants has a rich history of inkjet printing and we’ve now brought that expertise to the world of POC diagnostics. Combined with our extensive scientific and engineering knowledge—including our long track record in the low-cost, high-performance optics that many of these tests require—it’s resulted in a radical new way of providing diagnostics on demand.”
Related Links:
Cambridge Consultants
The new XylemDx technology developed Cambridge Consultants (Cambridge, UK) is set to bring a breakthrough innovation to POC diagnostics. Ingenious use of inkjet printing techniques has made it possible to create a test cartridge from a single sheet of paper, paving the way for sophisticated low-cost tests that can be adapted at the touch of a button. Also, the digital fabrication technique (once regulatory approval is secured) will give the flexibility to print tests in quantities from one to millions.
Aging populations, the drive for healthcare efficiency, and the rapid rise of “consumer healthcare”—where people manage their own health and well-being—are fueling an increase in POC diagnostics. But the high cost of POC tests compared with centralized lab tests is a challenge. XylemDx enables simple, low-cost, near-instant personalized testing, for example, at the pharmacy or doctor’s surgery, for signs ranging from the latest strain of the flu virus to biomarkers for genetic conditions. In developing countries, it could play a crucial role in mobile-clinic diagnostics and in pandemic monitoring and screening of large populations during an outbreak of Ebola, for example.
XylemDx turns a sheet of paper into any one of a variety of different tests, each of which can be produced on the same fabrication device. Each test paper can be configured with a custom set of test modules (such as electronic, thermal, fluidic, optical, or biological reagent modules) before being folded concertina-style into the traditional test cartridge shape. For diagnostic manufacturers, this opens up the possibility of low-cost prototyping and development, as well as a universal production methodology. The modules “toolbox” enables customization for a particular patient or specific strain of disease.
The test modules are printed with inkjet-based printing techniques that use wax to lay down fluidic pathways, electronic ink containing silver nanoparticles to allow electrical connectivity, and so on. The paper cartridges can be configured for various samples types (such as blood, urine, saliva, or mucus) and various readers (from complex diagnostic instruments to a reader on the back of a smartphone or a simple USB-powered device).
“Diagnostic tests underpin crucial healthcare decisions so it’s vital they are as fast, accurate, flexible, and cost-effective as possible,” said John Pritchard, head of diagnostics at Cambridge Consultants, “Cambridge Consultants has a rich history of inkjet printing and we’ve now brought that expertise to the world of POC diagnostics. Combined with our extensive scientific and engineering knowledge—including our long track record in the low-cost, high-performance optics that many of these tests require—it’s resulted in a radical new way of providing diagnostics on demand.”
Related Links:
Cambridge Consultants
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







 Analyzer.jpg)